ARCA Biopharma Inc. (Nasdaq: ABIO), a Westminster company known for its focus on genetically targeted therapies for cardiovascular diseases, has announced a significant update regarding its corporate strategy and planned merger with Oruka Therapeutics Inc. As part of the merger, ARCA plans to divest its legacy technology and intellectual property, including assets related to Gencaro…
Annual Membership Required
You must be a Annual member to access this content.
Already a member? Log in here